Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy-Reference-Cited by-同舟云学术

Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy

Published:2015-07 Issue:1 Volume:116 Page:75-81
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Samuels Stuart E.,Vainshtein Jeffrey,Spector Matthew E.,Ibrahim Mohannad,McHugh Jonathan B.,Tao Yebin,Schipper Matthew,Worden Francis,Eisbruch Avraham

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference24 articles.

1. Retropharyngeal lymph node metastases in head and neck malignancies;Coskun;Head Neck,2011

2. Prognostic influence of retropharyngeal lymph node metastasis in squamous cell carcinoma of the oropharynx;Dirix;Int J Radiat Oncol Biol Phys,2006

3. Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck;McLaughlin;Head Neck,1995

4. Human papillomavirus and survival of patients with oropharyngeal cancer;Ang;N Engl J Med,2010

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The molecular characteristics of recurrent/metastatic HPV‐positive head and neck squamous cell carcinoma: A systematic review of the literature;Clinical Otolaryngology;2024-04-24

2. Structured Literature Review to Identify Human Papillomavirus’s Natural History Parameters for Dynamic Population Models of Vaccine Impacts;Infectious Diseases and Therapy;2024-04-08

3. Incidence and predictive factors of retropharyngeal lymph node metastases in patients with oropharyngeal cancer undergoing multimodality treatment planning imaging;Head & Neck;2023-04-12

4. Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives;Cancers;2022-11-01

5. Magnetic Resonance-Guided Radiation Therapy for Head and Neck Cancers;Current Oncology;2022-10-31